Human Papillomavirus (HPV) research has been dominated by the study of a subset of Alpha papillomaviruses that together cause almost 5% of human cancers worldwide, with the focus being on the two most prominent of these (HPV16 and 18). These viruses are referred to as 'high-risk' (hrHPV), to distinguish them from the over 200 prevalent HPV types that more commonly cause only benign epithelial lesions. The 'low-risk' (lrHPV) term used to describe this group belies their cumulative morbidity. Persistent laryngeal papillomas, which occur rarely in children and adults, require regular surgical de-bulking to allow breathing. Such infections are not curable, and despite being caused by HPV11 (a lrHPV) are associated with 1-3% risk of cancer progression if not resolved. Similarly, the ubiquitous Beta HPV types, which commonly cause asymptomatic infections at cutaneous sites, can sometimes cause debilitating papillomatosis with associated cancer risk. Recalcitrant genital warts, which affect 1 in 200 young adults in the general population, and even the ubiquitous common warts and verrucas that most of us at some time experience, cannot be reliably eradicated, with treatment strategies advancing little over the last 100 years. The review highlights molecular similarities between high and low-risk HPV types, and focuses on the different pathways that the two groups use to ensure persistent infection and adequate virus shedding from the epithelial surface. Understanding the normal patterns of viral gene expression that underlie lesion formation, and which also prevent loss of the infected basal cells in established lesions, are particularly important when considering new treatment options. Finally, the common requirement for deregulated viral gene expression and genome persistence in development of cancers, unites both high and low-risk HPV types, and when considered alongside viral protein functions, provides us with a working understanding of the mechanisms that underlie HPV-associated pathology.
Fig. 1. Evolutionary Relationship between Human
Papillomaviruses. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) (A) The human papillomaviruses types found in humans fall into five genera, with the Alpha-, Beta-(blue) and Gammapapillomavirus (green) representing the largest groups; Human papillomaviruses types from the Alphapapillomavirus genus are often classified as low-risk cutaneous and low-risk mucosal (yellow); or high-risk (pink) according to their association with the development of cancer. The high-risk types highlighted with red text are confirmed as "human carcinogens" on the basis of epidemiological data. The remaining high-risk types are "probable" or "possible" carcinogens. Although the predominant tissue associations of each genus are listed as either cutaneous or mucosal, these designations do not necessarily hold true for every member of the genus. The evolutionary tree is based on alignment of the E1, E2, L1, and L2 genes (Doorbar et al., 2012) . HPV sequence data was obtained from PaVE (https://pave.niaid.nih.gov/#home). (B) The tropism and pathogenesis of each HPV species are listed. Tissue tropism has become controversial as a wide range of HPV DNA can be detected at mucosal and cutaneous sites from the general population. In fact, the sites of infection, and whether HPV is present as 'contaminating virus particles or as micro lesions or latent infection is not known yet. Each species tend to show a distinctive tropism when causative association with a lesion is demonstrated. The typical relationships between HPV type and disease are listed.
encompass the majority of the 200 or so known human papillomaviruses, cause benign hyper proliferative lesions, and are not a frequent cause of malignant carcinoma among the general population ( Fig. 1 ). Because of their lower impact as carcinogenic agents (and thus 'lower-risk') , research on lrHPV types has not been prioritized. In general, lesions caused by lrHPVs are self-limiting, and are eventually cleared by the host immune system, which is also the case for the hrHPV types that produce only asymptomatic infection in most individuals. However, among susceptible populations, lrHPV types can be refractory to treatment, and show problematic pathologies, including recurrent respiratory papillomatosis (RRP) and Epidermodysplasia Verruciformis (EV), and in these situations can sometimes be associated with the development of cancers. In this review, we overview the pathogenicity and carcinogenicity of lrHPV in comparison with hrHPV, and aim to emphasize that similar life cycle concepts explain many aspects of their pathogenesis, and some aspect of their infrequent carcinogenesis. As there are already a number of well-written reviews covering different aspect of this topic, our focus is on outline concepts, with the aim of keeping the review concise (Carifi et al., 2015; Doorbar et al., 2015; Egawa et al., 2015; Howley and Pfister, 2015; Quint et al., 2015; Roman and Munger, 2013; Vande Pol and Klingelhutz, 2013) .
Evolution and the prevalence of HPV-associated asymptomatic infections
With over 240 distinct human and animal papillomavirus types classified into 37 genera, with 5 genera of HPV spread among them (Alpha, Beta, Gamma, Mu and Nu), papillomavirus may perhaps be considered as one of the most successful families of vertebrate viruses (Bernard et al., 2010; de Villiers et al., 2004; Van Doorslaer, 2013) (Fig. 1) . Their origin is linked to changes in the epithelium of their ancestral host that occurred at least 350 million years ago. Since then, they have co-evolved with their various host species, paralleling the evolution of host resources or attributes, such as the presence or absence of fur or the evolution of sweat glands (Bravo and Felez-Sanchez, 2015; Van Doorslaer, 2013) . They are now found in birds, reptiles, marsupials and mammals. Through this route, papillomaviruses have each developed their distinctive molecular strategies, allowing each of them to complete their life cycle at specific sites of infection (Fu et al., 2010; Tan et al., 2012; Thomas et al., 2016; Van Doorslaer and Burk, 2010) , and as a consequence of this, they show remarkable species specificity and a great diversity of epithelial tropisms and clinical pathologies. Unfortunately, our understanding of these adaptations is very limited, as most research has focused on the oncogenic property of viral genes and the process of malignant progression, rather than virus fitness and evolutionary adaptation to a specific epithelial site. It seems in fact that lrHPV types are maintained and propagated in the general population as successfully as the oncogenic high-risk types de Koning et al., 2007 de Koning et al., , 2010 Desai et al., 2011; Stanley et al., 2012; Weissenborn et al., 2012) . Interestingly, the non-productive or abortive hrHPV infections that represent the precursors of HPV-associated cancer are not obviously beneficial from a virus-fitness point of view and the precise reason why hrHPV and lrHPV have evolved such distinctive life cycle behaviours remains to be elucidated.
Low-risk HPV types and their organisational similarities with high-risk types
HPV infections are ubiquitous, and a plethora of both high and low risk HPV types reside on the skin of immunocompetent individuals without signs of symptomatic lesions, forming part of the normal microbial skin flora (Antonsson et al., 2003a,b; de Koning et al., 2015; de Koning et al., 2007; Poljak et al., 2009; Potocnik et al., 2006) . Some specific HPV types have a tendency to induce symptomatic hyper-proliferative lesions in the general population, with genotype-specific pathogenicity and tropism Egawa et al., 2015) . In general, these infections are self-limiting, and will eventually be cleared by the host immune system. Some individuals fail to clear such lesions however, and if uncontrolled they can cause clinical problems, as occurs with RRP, EV and in the case of hrHPV infection, cervical cancer and cancer at other epithelial sites.
Despite diversity amongst the lesions that different HPVs cause, they share many similarities in their life cycle organisation. First of all, HPVs infect long-lived basal epithelial cells, including stem or stem-like cells (Egawa, 2003; Egawa et al., 2015; Herfs et al., 2013 Herfs et al., , 2012 , or may modify the infected basal cell to extend its lifespan and confer stem-like characteristics. The precise target cell for HPV infection is thought to vary according to HPV type, with cells in the hair follicle bulge being proposed for members of the Beta Genus and for animal papillomavirus such as CRPV Schmitt et al., 1996; Weissenborn et al., 2012) . At inter follicular epithelial sites, the existence of slow cycling 'stem cells' which maintain the epithelium is still hotly contested, and their existence need not in fact be invoked to explain epithelial dynamics (Roshan et al., 2016) . It is in fact disappointing, that the site-specific regulation of the target tissues that HPVs infect are not better understood (reviewed in ). Despite the extensive studies carried out on hrHPV-association and cervical cancer, our understanding of the very early stages of disease formation, even at this site, remains quite rudimentary (Herfs et al., 2013; Herfs et al., 2012; Mirkovic et al., 2015) . Even so, we believe that all papillomaviruses must establish themselves in the lowest epithelial layers where mitotically active cells are found, and that they persist in these cells as a multi-copy circular extra-chromosomal elements (episomes). The episomal copy number in these basal cells is often quoted as around 200/cell, but the techniques needed to accurately assess this in vivo have not yet been widely implemented, and for the hrHPVs, basal copy number has been assumed to be similar to the copy number seen when HPV genomes are propagated in cells in tissue culture (Hoffmann et al., 2006; Hummel et al., 1992; Stanley et al., 1989) . In the absence of host immune regulation, a wide range of episomal copy numbers are seen in tissue culture models, being dependent on cell culture conditions and the particular HPV type. Although further work is certainly required to fully understand site and HPV type-specific variations, where basal cell copy number has been measured in vivo using laser capture methods, approximately 50 copies per cell were observed (Maglennon et al., 2011) . For both hr and lrHPV genomes, replication occurs once per cell cycle on average in undifferentiating/proliferating basal cells, with limited viral gene expression to minimise the chance of immune detection. Indeed, we suspect that viral proteins such as E7 and E1 may be dispensable for maintenance replication (Egawa et al., 2012; Kim and Lambert, 2002) with E2, which is involved in genome segregation being one of the limited number of essential viral gene products required for genome maintenance. The elevated expression of the hrHPV E6/E7 proteins that drive neoplasia, may be tolerated in part, because these proteins have complex immune evasion functions, and can suppress cytokine signalling and the presentation of foreign peptides to dendritic cells (reviewed in (Roman and Munger, 2013; Stanley, 2006; Stanley et al., 2012; Stanley, 2012; Vande Pol and Klingelhutz, 2013) . In fact, we suspect that although the low risk E6 and E7 proteins may not obviously influence basal cell division, that these proteins may modulate basal layer cell density, or function transiently at particular stages of the lrHPV life cycle, such as during lesion formation. Although both hr and lrHPV types have mechanisms to limit transition from the basal to parabasal cell layers in order to sustain infection, the differentiation process is essential if productive virions are to be produced and transmitted (Doorbar et al., 2012; Roman and Munger, 2013; Vande Pol and Klingelhutz, 2013) . HPV conducts this phase of the viral life cycle with a relatively small number of viral gene products expressed from either its 'core' or 'accessory' genes ( Fig. 2) . In general, the core genes must have existed early during papillomavirus evolution, and their essential functions in viral genome replication and genome packaging are conserved, even when distantly related PV types are compared. By contrast, the 'accessory' genes encode proteins that modify the cellular environment, and include the E6 and E7 proteins that can drive cell cycle entry and sometimes also cell division and the E5 protein that can mimic EGFR signalling activated in the suprabasal layer, irrespective of normal extracellular regulatory signals. The accessory genes, and the transcriptional controls that regulate them, have a major influence on the various diseases that the different HPV types cause, and as a general rule, they perform similar, but not necessarily identical functions during the life cycle of different papillomaviruses, to support virus synthesis and affect virulence. One of the major differences that mark the lowrisk HPV types from high-risk, is that the former do not typically use their E6 and E7 gene products to drive extensive cell proliferation in the basal and parabasal cell layers. This is a consequence of the different transcriptional regulation of these genes in low-risk papillomaviruses, and also to differences in viral protein function. An important consequence of this is reflected in the poor ability of low-risk HPV types to drive neoplasia and to drive cancer progression.
The changes in viral gene expression that eventually trigger genome amplification and capsid assembly are broadly similar across all papillomavirus types, irrespective of their high or low-risk designation. For lrHPV types, E6/E7-mediated cell cycle reentry restores a replication-competent environment in the infected post-mitotic cell, but does not drive cell division (Fig. 3) . In these cells, E1 and E2 levels rise as a result of late promoter activation (Bodily et al., 2013; Flores and Lambert, 1997; Ozbun and Meyers, 1997; Ozbun and Meyers, 1998; Ruesch et al., 1998; Spink and Laimins, 2005) , allowing the viral and cellular gene products to work together to amplify the nuclear HPV episomes. It is unclear whether limited cellular DNA replication accompanies the viral genome amplification process, although several reports have suggested that as with other viruses, cellular replication is inhibited (DeSmet et al., 2016; Ginsberg and Dixon, 1961; Petrik et al., 2006) . Although high-risk HPV types can sometimes also drive cell cycle re-entry in this way, the looser regulation of E6/E7 expression in neoplasia means that genome amplification can also occur in cells that have remained in cycle from basal layer upwards. A primary function of E6 and E7 in the life cycle of all papillomaviruses therefore, is to limit keratinocyte differentiation in the basal layer to retain the reservoir of infection, and to drive differentiating cells into a replication-competent state for genome amplification in the suprabasal layers (Roman and Munger, 2013; Vande Pol and Klingelhutz, 2013) . Virion assembly requires the timed expression of L2 and L1 post-genome amplification, and the accumulation of (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) (A) Genome organization typical of the high-risk (HPV16), low-risk (HPV11) Alphapapillomavirus and Betapapillomavirus (HPV5) types is illustrated. The early (p97) and late (p670) promoters in HPV16 are marked by arrows. The five or six early ORFs (E1, E2, E4 and E5 (in green) and E6 and E7 (in red)) are expressed from the different promoters at different stages during epithelial cell differentiation. The late ORFs of HPV16 (L1 and L2 (in yellow)) are expressed from the p670 promoter in the upper epithelial layers as result of changes in splicing. The LCR/URR also contains the replication origin as well as post-transcriptional control sequences that contribute to viral gene expression. (B) The function of viral proteins. All known papillomavirus encodes a group of "core" proteins that were present early on during papillomavirus evolution, and which are conserved in sequence and in function between PV types. These include E1, E2, L2 and L1. The E4 protein may also be a core protein that has evolved to meet papillomaviruses epithelial specialization. The accessory proteins have evolved in each papillomavirus type during adaptation to different epithelial niches. The sequence and function of these genes are divergent between types. In general, these proteins are involved in modifying the cellular environment to facilitate virus life cycle completion, contributing to virulence and pathogenicity. Proteins functions of Gamma, Mu and Nu papillomaviruses have not been investigated to the same level as those of the Alpha and Beta types. *1 (White et al., 2014) , *2 (Cordano et al., 2008) . Fig. 3 . The different function and expression of viral proteins underlies disease phenotype. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) (A) In uninfected epithelium, cell cycle entry (red nuclei) and cell division in the basal/parabasal cell layers is controlled by cell density and growth factors. In the suprabasal layer, cells exit the cell cycle and start to terminally differente (keratinization). (B) In lesions caused by low-risk Alpha HPV types, it is thought that basal cell proliferation is largely regulated by the presence of growth factors. The primary role of the HPV E6/E7 proteins in these lesions is to drive cell cycle entry above the basal layer in order to facilitate HPV genome amplification (red nuclei in mid epithelial layers). This is thought to be dependent on the ability of E7 to bind the Rb family member p130. Little or no E6/E7 expression is thought to occur in the basal layer, and the precise role of these proteins in basal cells is not known. E6/E7 may limit keratinocyte differentiation in the basal layer, or increase the population of infected cells to drive "Papillomatosis" and to retain the reservoir of infection. (C). In high-risk Alpha HPV infections, expression of the high-risk E6/E7 proteins in the basal layer leads to cell proliferation and evasion from host immune surveillance. In these cell populations, malignant transformation is may develop. the viral E4 protein involved in virus release and survival (Doorbar, 2013) .
What functions do low-risk HPV types lack and what marks them apart?
Although lrHPV research has not been prioritised, our understanding of hrHPV gene function and molecular biology is relatively advanced, and it is perhaps easiest to look initially at the additional E6/E7 functions possessed by this group of viruses. hrHPV E6/E7 function has been investigated primarily in the context of carcinogenesis, which is understandable given that hrHPV-associated cancers are characterised by the continued expression of these gene products (Roman and Munger, 2013; Vande Pol and Klingelhutz, 2013) . The progressive E6-mediated loss of p53 and the activation of hTERT, accompanied by a comparable degree of E7-mediated pRb inhibition, underlies many of the hrHPV's transformation and oncogenic properties. In addition, a wide range of important biological and biochemical activities are associated with the hrE6 and E7 proteins, including the modulation of PDZ protein functions involved in cell-cell communication (Ganti et al., 2015) , the induction of chromosomal instability, and the evasion of the adaptive and innate immune responses that contribute to persistence and carcinogenesis (Roman and Munger, 2013; Tummers and Burg, 2015; Vande Pol and Klingelhutz, 2013) . Curiously, the lrHPV E6 and E7 proteins, and particularly those encoded by low risk Alpha HPV types, have often been regarded as less potent versions of the hrHPV proteins, which neglects their important role in driving successful lrHPV infection. An exception comes from the growing number of Beta-HPV types, which can be considered as low-risk in the general population, but higher-risk in particular susceptible groups, including SCID (severe combined immunodeficiency) and EV patients. Once again, the functions of the Beta HPV gene products have been studied primarily because of their sporadic association with cancer, and from this we have gleaned important insight into the way they use their genes during productive infection. The Beta HPV types (and indeed, those of the Gamma HPV Genus as well) show a remarkable functional difference in their E6 proteins when compared to hrHPV types from the Alpha Genus. Instead of binding the ubiquitin ligase E6AP, which is necessary for the degradation of p53, the Beta HPV E6 proteins recognise a similar but subtly different motif in the MAML protein (Brimer et al., 2012; Meyers et al., 2013; Tan et al., 2012) . Curiously, MAML is a downstream component of the Notch signalling pathway, which controls normal basal cell differentiation, and its regulation points to a role for the Beta HPV E6 protein in preventing loss of the infected basal cell from the epithelial basal layer. As mentioned previously, this is also a role for the hrHPV E6 protein, although here the effect is achieved through p53, which regulates Notch levels indirectly through transcription (Yugawa et al., 2007) . When taken together, it is becoming clear that irrespective of high or low-risk status, persistent infection requires that these viruses make common changes to the cells that they infect, and that there is convergence in the pathways that they affect (reviewed in (Vande Pol and Klingelhutz, 2013) ). Indeed, the Beta HPV types have well characterised effects on proteins that regulate apoptosis, including Bak & FADD (Neveu et al., 2012; Simmonds and Storey, 2008; Underbrink et al., 2008 ), but curiously not on p53, which is a common target of Alpha HPV types, and a potent stimulator of apoptosis and/or growth arrest. The different ways that these proteins affect the cell, almost certainly underlie the different regulation at the different epithelial sites that they infect. Moving our focus from cancer to productive infection, and from high to low-risk HPV types will in due course allow the development of new intervention strategies for the problematic diseases that these viruses cause. Unfortunately, the lr Alpha HPV types are not understood at this level, although it is known that their E6 proteins can modulate p53 function, albeit less dramatically, and their E7 proteins target Rb family members, although here it is suggested their preference is for p130, which regulates cell cycle entry in the upper epithelial layers, rather than p105 and p107, which control these processes in the basal and parabasal layers (Barrow-Laing et al., 2010; Zhang et al., 2006) . It is apparent from this that the different protein functions, and the way that these are expressed during the virus life cycle, directly underlie viral pathogenesis. The link between viral gene function and the timing of HPV gene expression during the virus life cycle, remains however a little unclear.
Only the viral structural proteins (L1 and L2) and the abundant E4 amyloid-like structures are easily detected in clinical material, and although E2 and E7 have been localised in lesions caused by some hrHPV types, the limited availability of good antibodies precludes their detection in lesions caused by lrHPV types (Ressler et al., 2007; Xue et al., 2010) . Similarly, RNA mapping studies, have not yet been used to fine-map transcriptional patterns layer by layer in infected epithelium (Egawa et al., 2000; Evans et al., 2014; Stoler et al., 1989) . We know however that the regulation of E6 and E7 gene expression is regulated very differently between hr and lr HPV types, with hr types regulating E6/E7 ratios by differential splicing, whereas lr HPV types such as HPV11 use separate promoters to control the expression of these genes. This different regulation almost certainly influences the propensity of hrHPV gene expression, but not that of lrHPV types, to become deregulated at particular epithelial sites. While the restricted expression of viral genes is sufficient for basal cell genome maintenance and persistence, it is clear that situations that favour deregulation can lead to neoplasia Evans et al., 2014) . With this in mind, the typically lrHPV types such as HPV5 and 8 from the Beta Genus, or HPV11 which causes RRP, can also sometimes also cause cancers, but that the circumstances that allow them to do this are less likely. Host genetic susceptibility and immune suppression are required for these viruses to persist with deregulated patterns of gene expression.
Although we remain unclear as to the specific advantage that the different transcriptional organisation and the more aggressive protein functions offer the hrHPV types, these have greatly facilitated their study in tissue culture systems. hrHPV types impart a marked growth advantage on the cells they infect, which for the reasons described above, lrHPV types cannot do. lrHPV types do not immortalize keratinocytes in culture, and to date it has proved difficult to reliably reproduce their productive life cycle in organotypic raft culture. This, coupled with the limited molecular understanding of natural in vivo infection, continues to limit our understanding of these viruses.
The pathogenesis of lrHPV types; papillomas, papillomatosis and the prospect of malignant progression
lrHPVs cause a wide range of apparent benign lesions, including genital warts (HPV 6 and 11), common warts (HPV 2, 27 and 57), flats warts (HPV 3 and 10), verrucas or myrmecia (HPV 1) as well as many other skin lesions (see a review at 2015 ). These infections are quite common. The incidence of new cases of genital warts per year in UK is 0.16% (Woodhall et al., 2008) . HPV associated cutaneous disease is more common in the general population, particularly in children who lack previous HPV exposure (de Koning et al., , 2010 . In general, such lesions are self-limiting, not life threatening, and in most cases will eventually be cleared by a cell mediated immune response (Sterling et al., 2001) . HPVassociated papillomas are highly refractory to treatment however, persisting for years, and posing a problem cosmetically, psychologically and practically depending on the number of lesions and the site of infection (Woodhall et al., 2011) . Indeed, the total cost to the healthcare system in England for the treatment of genital warts is currently estimated at £16.8 million/year (Desai et al., 2011) .
Despite their low-risk designation, HPV 6 and 11, as well as other low-risk HPV types including HPV42, 44 and 70 DNA are sometimes detected in invasive cervical and anal cancers, but it is quite rare (Cornall et al., 2013; Guimera et al., 2013a,b; Li et al., 2011) . A wide range of HPV types is detected in Bowen's disease, which is a squamous cell carcinoma in situ, and in non-melanoma skin cancer, but hrHPV types are generally much more common than other HPV types (Alam et al., 2003; Forslund et al., 2007; Zheng et al., 2005) . lrHPV infections are not considered a significant causative agent of malignant transformation in the general population, and the link between lrHPV and carcinoma remains unclear except in immunosuppressed individuals and in certain genetic backgrounds (discussed below). In these situations, it appears that the progression route of hr and lrHPV types towards cancer is quite different. One of the best examples of this is provided by the rare inherited condition 'Epidermodysplasia verruciformis' (EV), but analogies can be made to Beta HPV-associated cancers in the individuals who are immunosuppressed, either iatrogenically or as a result of an inherited condition. EV is a rare autosomal recessive disorder that may be linked to zinc balance defect in keratinocytes and lymphocytes (Lazarczyk et al., 2012; Lutzner, 1978; Notarangelo et al., 2004) . EV patients develop pityriasis versicolor-like lesions and flat warts that can undergo malignant transformation to SCC in approximately 30-50% of cases, usually in sun-exposed body sites (Orth, 2006; Orth et al., 1978) . Individuals with EV have an unusual susceptibility to Beta HPV infections (Lazarczyk et al., 2009; Orth, 2006) . Beta HPV infection is asymptomatic in the general healthy population, with beta-HPV DNA being detected in plucked eyebrow hairs in the absence of apparent lesions. In immunosuppressed individuals such as transplant recipients or HIV positive patients, these viruses can produce visible papillomas (a situation sometimes referred to as 'acquired EV' (Connolly et al., 2014; Lutzner et al., 1983) ), indicating that the host immune system usually clears and controls beta-HPV infection in the general population. Certain Beta HPV types are a significant cause of non-melanoma skin cancer in susceptible individuals such as EV patients, through a mechanism that is somewhat distinct from that characterised for the hr Alpha HPV types . High-risk papillomaviruses actively drive basal cell proliferation and also inhibit differentiation, and during this process they accumulate chromosome abnormalities and point mutations in the infected basal cell. To a large extent, these mutations, which are essential drivers of the cancer phenotype, result from E6/E7 overexpression, and the consequences that this has on the cellular targets of these proteins, including p53 (Duensing and Munger, 2004) . In most if not all cases, maintenance of the cervical cancer phenotype requires the continued expression of the viral E6 and E7 proteins, which often occurs from integrated rather than episomal hrHPV genomes (Pett and Coleman, 2007; Pett et al., 2004 Pett et al., , 2006 , with several studies showing that HPV-driven cancer cell lines undergo apoptosis when E6 function is inhibited (Butz et al., 2003; Jiang and Milner, 2002) . In the case of Beta HPVdriven cancers, the situation is slightly different . As with the hrAlpha types, some degree of deregulated viral gene expression is first required, as it is deregulation, rather than the highly ordered patterns that characterise productive infection, that predispose to cancer progression. This deregulation is tolerated in an immunosuppressed or EV background, but not generally in an immunocompetent host (Lazarczyk et al., 2009 (Lazarczyk et al., , 2012 (Lazarczyk et al., , 2008 . It is thought that the subversion of normal Beta HPV function (E6 in particular) in inhibiting apoptosis and in preventing differentiation, prevents cell death or cell loss from the basal layer as secondary genetic mutations accumulate (Jackson and Storey, 2000; Muench et al., 2010; Struijk et al., 2008; Underbrink et al., 2008) . This fits well with the observation that Beta HPV-associated cancers occur at sun-exposed sites and can take decades to develop (Connolly et al., 2014; Lutzner, 1978; Lutzner et al., 1984 Lutzner et al., , 1983 . Indeed, it has been suggested that Beta HPV types may contribute to skin cancer in the general population at sun exposed sites (Forslund et al., 2007; Howley and Pfister, 2015) , which is plausible given that UV exposure and inflammation itself can modulate virus promoter activity. The failure to reproducibly find Beta HPV DNA in the subsequent cancers has been taken by some to argue against this possibility, and has compromised attempts to provide epidemiological supporting data. However, given that the Beta HPV cancer model requires E6 and E7 only for the accumulation of genetic errors and not for maintenance of the cancer phenotype, it has so far been impossible to rule out the possibility that these viruses may contribute to cancer incidence via a hit and run mechanism.
A second lrHPV cancer association is linked to recurrent respiratory papillomatosis (RRP), which is briefly described above, and which is typically associated with HPV11 (Goon et al., 2008) . In susceptible individuals, laryngeal papillomas can persist for decades, re-growing after surgical removal, and in some instances, giving rise to metastatic lesions in the lower airway and lung (Gerein et al., 2005) . The viral genome can be integrated into the host cell chromosome in these cancers, suggesting deregulated viral gene expression followed by the acquisition of additional genetic and epigenetic modifications as seen for the hr Alpha HPV types (Huebbers et al., 2013; Reidy et al., 2004) . Rearranged HPV11 genomes have also been observed in some of the RRP-associated cancers, but so far the patterns of viral gene expression have not been characterised. Compared to the prevalence of lrHPV (Broker et al., 2001 ), RRP is rare (1.42 patients per 100,000 in UK (Donne et al., 2016) ), suggesting that RRP should be regarded as a multigene disease, in which there is a HPV type and tissue-specific immune deficiency that prevents the effective clearance and control of HPV 6 and 11 infections, similar to the situation with Beta HPV types in EV (Bonagura et al., 2010) . Among these patients, HPV6 and HPV 11 should therefore be treated as a hrHPV, with a requirement for long term follow up. In general however, we suspect that the different E6/E7 regulatory controls, both at the level of protein function and gene expression, may also restrict the cancer associations of lr papillomaviruses, even in susceptible individuals.
Collectively, the pathogenicity of HPV is determined not only by HPV genotype but also by the epithelial micro-environment at the site of infection (Egawa et al., 1993) , and for the hrHPV types this also extends to carcinogenesis, which is seen at higher levels at particular susceptible epithelial sites in the body (reviewed at 2015 ). For the lrHPV types, cancer association is very rare in the general population, and requires either a host genetic susceptibility, or immunosuppression to allow elevated viral gene expression and the appearance of recalcitrant lesions that may develop a malignant potential. During evolution, each HPV has evolved a distinctive strategy to maximizing its fitness in its specific niche, with both high-and low-risk HPVs being successfully propagated in the general population. To fully explain why lrHPV, and also the intermediate risk HPV types, do not cause malignant progression at the levels seen with the hr types, requires an increase in our understanding of the site-specific molecular pathogenesis of these viruses at the level of viral gene regulation and protein function.
Conclusions
The pathogenesis of HPV is determined by viral protein function, as well as the way in which these proteins are regulated, and clearly this is influenced by the host as well as the microenvironment at the specific site of infection. Host immune status and genetic background are both well-established susceptibility factors for virus-associated cancers, and not just those cancers caused by HPV. The deregulated expression of normal viral gene products, that when properly controlled play an essential life cycle role, is the unifying feature of all papillomavirus-associated precancers. The different frequency of hr and lrHPV associated cancers seen in the general population reflects the different propensity for viral gene expression to become deregulated, and the ability of their proteins to subvert important cellular regulatory pathways when this happens. Data obtained following the introduction of hrHPV vaccines shows promising effectiveness in prevention of cervical neoplasia and genital warts caused by some HPV types (Drolet et al., 2015) , suggesting that HPV infection can be controlled by prophylactic vaccination. The development of effective strategies for disease treatment (e.g. targeted antivirals, immunotherapeutics) and disease management (e.g., risk assessment) are however still required if we are to address the wide diversity of diseases that these viruses cause. 
